PDCD1 and autoimmune disease: In combination with immune checkpoint inhibitors, criteria such as the concomitant use of steroids, the administration of immunosuppressants, and the exclusion of patients with underlying autoimmune diseases were applied, considering the occurrence of autoimmune adverse reactions (irAEs), and in preclinical trials, ganetespib showed an immunomodulatory effect that alleviated anti-PD-1 antibody hypersensitivity and increased T cell activity [60,134].